Santaris Pharma

drug development for cancer therapeutics based on PNA (peptide nucleic acid) and LNA (locked nucleic acid) technology

History:

Formed from the merger of Pantheco and Cureon in 2003.

Employment

Email:

Fax:

Mail:

General Info:

Ticker:

Employees:

Regions:
Europe

Research Focus:
RNAi Disease Therapeutics-Research

 

Profiles:

 

News:

Keywords: 

Strategic Partnerships: